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T
his is the fourth of a series of articles
based on presentations at the Amer-
ican Diabetes Association Scientiﬁc
Sessions held 5–9 June 2009 in New Or-
leans,Louisiana,pertainingtobloodpres-
sure and renal disease in diabetes.
Diabetic nephropathy and obesity
At the Clinical Update in Diabetic Ne-
phropathy at the American Diabetes As-
sociation Scientiﬁc Sessions, Karen A.
Grifﬁn (Maywood, IL) discussed interre-
lationships between obesity and the kid-
ney, noting that obesity appears to be
related to the increase in end-stage renal
disease (ESRD), in part because of its re-
lationship to diabetes and hypertension,
but with a 1.2-to 1.6-fold increase in
chronic kidney disease (CKD) risk even
correcting for these associations. Review-
ing CKD staging, in stages 3, 4, and 5, the
glomerular ﬁltration rate (GFR) is 30–59,
15–29, and 15 ml/min per 1.73 m
2
BSA,respectively,andGrifﬁnpointedout
that the adjustment for body surface is
quite important when considering the ef-
fect of body size. In a Kaiser Permanente
analysis of 1,471 subjects developing
ESRD in a 8,347,955 person-year follow-
up, adjusted for age, sex, race, education,
cigarette use, diabetes, blood pressure,
lipids, and other variables, obesity in-
creased the likelihood of ESRD with BMI
35 associated with a 5-fold increase,
BMI 30–34.9 associated with a 3-fold in-
crease, and BMI 25–29.9 associated with
a 1.5-fold increase in risk (1). There are a
number of different forms of obesity-
related CKD, with the majority of cases
associated with microalbuminuria, en-
dothelial dysfunction, and mild-to-
moderate decrease in GFR, mainly
associatedwithcardiovascularrisk.Coex-
istent obesity and CKD lead, however, to
acceleratedprogressionofthelatter(2,3).
A form of glomerulopathy occurs with
obesity characterized by glomerular en-
largement (which is more common in
obesity)andfocalsegmentalglomeruloscle-
rosis (4). The pathogenesis may involve hy-
perﬁltration,leadingtoglomerularcapillary
injury and sclerosis, in a fashion similar to
occurringexperimentallywith5/6nephrec-
tomy (5). From a hemodynamic point of
view, there is a high GFR in obesity (6)—a
phenomenon demonstrated in comparison
of body mass among a variety of different
mammalian species. GFR decreases after
weight loss in morbid obesity (7,8).
Grifﬁn noted that hyperﬁltration,
whichoccurswithlossofrenalmass,asin
renaltransplantdonors,orwithincreased
metabolic requirement, as in pregnancy,
predominantly reﬂects increased glomer-
ular capillary ﬂow rather than an increase
in glomerular pressure. Most patients
with hypertension develop benign ne-
phrosclerosis, other than at extremely
high blood pressure levels, while those
with nonproteinuric CKD and, to an even
greater extent, those with diabetic ne-
phropathy and other renal diseases de-
velop renal damage in a fashion related to
blood pressure but at much lower blood
pressure levels (9); Grifﬁn showed exper-
imental models of this (10), supporting
the recommendation that blood pressure
goals in persons with diabetes or with re-
naldiseaseshouldbelowerthanthosefor
the overall population with essential
hypertension.
Thereareprotectiverenalautoregula-
tory mechanisms that reduce susceptibil-
ity to hypertensive damage (11,12) in the
absenceofrenaldisease.Obesitydoesnot
in itself result in increased susceptibility
tolossofrenalautoregulation,butthereis
an eightfold variation in number of glo-
meruli per kidney present at birth, with
lowernumberinsubjectswithlowerbirth
weight (a risk factor for insulin resis-
tance), with the number not changing
subsequently (13). Obese individuals
who happen to have a low glomerular
number may then be at greater risk of ex-
treme increase in glomerular size and
hence of developing pressure injury, with
increase in glomerular size potentially in-
creasing the susceptibility to injury by in-
creasing glomerular capillary wall stress
(14). Grifﬁn concluded by proposing a
multihit concept of the pathogenesis of
progressiveglomerulosclerosisinobesity,
based on the combination of decreased
nephronnumberand/orotherunderlying
CKD increasing likelihood of deteriora-
tion in the face of the glomerular hyper-
ﬁltration and increase in glomerular size
developing from the obesity itself (15).
Diabetic nephropathy and vitamin D
Rajiv Agarwal (Indianapolis, IN) dis-
cussed effects of vitamin D on diabetic
nephropathy and on the progression of
CKD. A small but rather inﬂuential study
carried out 3 decades ago randomized
subjects with GFR 35 ml/min to 1,25-
dihydroxyvitamin D (1,25-D) (1 g
daily) or to vitamin D3 (4,000 units
daily), ﬁnding increased progression of
lossofGFRwiththeformer(16).Agarwal
observed, however, that high dosages
were used, with the majority of those re-
ceiving calcitriol developing hypercalce-
mia, and that the duration of treatment
was overly short. Nevertheless, the con-
ceptthatvitaminDshouldnotbegivenin
CKD was put forward, hampering devel-
opment of the ﬁeld. 25-hydroxyvitamin
D [25(OH)D] is taken up by a speciﬁc
proximal tubular receptor, then 1-
hydroxylated to 1,25-D, which then cir-
culates to act in other tissues. There are,
however, extra-renal 1-hydroxylation
systems in tissues such as the monocyte,
leading to intracellular or paracrine ef-
fects, with subsequent intracellular inac-
tivation. Vitamin D has a number of
potentiallybeneﬁcialrenaleffects,includ-
ing renin-angiotensin system (RAS) inhi-
bition by an action of the vitamin
D/vitaminDreceptor/RXRheterodimerto
downregulate renin gene transcription,
effects on insulin resistance, effects on
vascular smooth muscle and endothe-
lium, and activation of antibacterial ac-
tion in monocytes and macrophages.
Vitamin D also downregulates transform-
inggrowthfactor(TGF)-,decreasingtu-
bularinterstitialﬁbrosis,andhasaneffect
on the mesangial cell to decrease glomer-
ulosclerosis. Studies are beginning to
emergeinman.Theprevalenceofvitamin
D deﬁciency increases, and parathyroid
hormone(PTH)increaseswithdecreasing
GFR, but not only is there the expected
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
Zachary T. Bloomgarden, MD, is a practicing endocrinologist in New York, New York, and is afﬁliated with
the Division of Endocrinology, Mount Sinai School of Medicine, New York, New York.
DOI: 10.2337/dc10-zb03
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
Reviews/Commentaries/ADA Statements
PERSPECTIVES ON THE NEWS
e30 DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 care.diabetesjournals.orglow level of 1,25-D but also a low level of
25(OH)D. Proteinuria levels also are in-
versely proportional to the 25(OH)D
level, well below nephritic proteinuria
levels. Agarwal noted that there is a
lower prevalence of hypertension in lati-
tudes closer to the equator with greater
sun exposure (17), suggesting that this
might be related to vitamin D status.
1,25(OH)D may act directly to decrease
vascular smooth muscle proliferation, and
25(OH)D deﬁciency is associated with
vascular stiffness and endothelial dys-
function, with no evidence that subjects
with ESRD and higher vitamin D levels
have greater degrees of arterial calciﬁca-
tion (18). There is a sixfold higher inci-
dence of hypertension in persons with
25(OH)D 15 ng/ml compared with
thosewithlevels30ng/ml(19),andthe
1,25(OH)D quartile also is associated
with both systolic and diastolic blood
pressure (20). In a study comparing cal-
cium supplementation alone or in combi-
nationwithvitaminD,notonlywerePTH
levels reduced, but blood pressure was
lower in the latter group, suggesting that
deﬁciencymaycontributetothedevelop-
ment of hypertension (21). Agarwal also
reviewed his study of 220 subjects with
stages 3 and 4 CKD showing an antipro-
teinuric effects of the vitamin D receptor
agonist paricalcitol, with 14% of those re-
ceiving placebo versus 31% of those re-
ceiving paricalcitol having reduction in
dipstick proteinuria. Improvement was
seen regardless of use of ACE inhibitors
(ACEIs)/angiotensin receptor blockers
(ARBs), suggesting an upstream effect on
insulinresistance,ontheTGF-pathway,
or on inﬂammation (22). Parenthetically,
he noted that dipstick proteinuria shows
considerably better correlation than usu-
ally recognized with the protein-to-
creatinine ratio (23,24); we have shown
similar correlation in assessment of mi-
croalbuminuria (25). In Agarwal’s 24-
person pilot study of placebo versus
paricalcitol treatment of patients with
25(OH)D deﬁciency, albuminuria and
measures of inﬂammation decreased; a
larger trial is ongoing.
Treatment for diabetes with renal
disease: what works?
Alan Go (San Francisco, CA) reviewed
studiesofdiabeticnephropathyincluding
clinical cardiovascular and renal end
points rather than proteinuria per se,
pointing out what appear to be more or
less useful treatment approaches. The
Steno-2 trial of 160 type 2 diabetic pa-
tients with microalbuminuria showed
that an 8-year multifactorial intervention
with glycemic control, RAS blockers, as-
pirin, and lipid lowering led to a 46% re-
duction in all-cause mortality after an
additional 5-year period of observation
(26). Improvement in nephropathy was
seen at 4 and 8 years, with a 56% reduc-
tion in new and worsening nephropathy
and an absolute 6% decrease in the need
fordialysis.Anothersomewhatencourag-
ing intervention that Go described used
anelectronicregistry,visitreminders,and
patient-speciﬁcphysicianalertsin69,965
visits from 8,405 adult patients with type
2 diabetes at 238 health care providers in
24 practices from 17 health systems to
achieve systolic blood pressure 130
mmHg, A1C 7%, and LDL cholesterol
100 mg/day; 12.6% of intervention vs.
8.5% of control patients achieved these
goals—certainly important outcomes, al-
though considerably less than the im-
provement found in process measures
(27). In a trial of the direct renin inhibitor
aliskiren, 599 type 2 diabetic patients
with albuminuria, all treated with losar-
tan (100 mg daily), were randomized to a
placebo versus addition of 150 mg then
300 mg aliskiren. Proteinuria decreased
by 18–20% with a trend to less reduction
in GFR although with no signiﬁcant im-
pact on systolic blood pressure; the study
was not powered to examine clinical
events (28).
Otherapproachesdonotappeartobe
as useful. A study comparing the ARB
telmisartan with the ACEI ramipril with
the combination of both included more
than9,600diabeticpatientswith4.7-year
follow-up, showing noninferiority of the
two individual treatments (29). Disap-
pointingly, however, there was no addi-
tional beneﬁt of combined treatment.
Telmisartan treatment showed a trend to
reduced GFR, and combined treatment
showed signiﬁcantly lower GFR, despite
lower levels of albuminuria with these
treatments than with ramipril (30),
arguing against the hypothesis that al-
buminuria can be used as a marker of
nephroprotection. Furthermore, a study
of 5,927 ACEI-intolerant high-risk pa-
tients with end-organ damage followed
for56monthsshowednosigniﬁcantben-
eﬁt of telmisartan versus placebo, with
particularly little evidence of beneﬁt in
patients with diabetes and with a trend to
faster rate of decline in GFR with telmis-
artan, despite the agent being associated
with lesser increase in albuminuria; elim-
ination of patients followed for shorter
periods, and of heart failure hospitaliza-
tionasanendpoint,didgiveasuggestion
of beneﬁt (31). Similarly, treatment with
telmisartan beginning soon after an isch-
emic stroke and continued for 2.5 years
did not signiﬁcantly lower recurrent
stroke,majorcardiovasculareventrate,or
diabetes (32).
Go reviewed several studies of statin
treatment in subjects with CKD. Post hoc
analysis of a trial comparing atorvastatin
10 mg with 80 mg daily in 1,501 diabetic
patients showed that among the 546 pa-
tientswithstage3–4CKDthehigherdose
of atorvastatin was associated with more
substantial evidence of reduction in car-
diovascular outcomes than was seen in
those with normal GFR, as well as with
greater increase in GFR (33). In a study of
2,776patientswithESRDundergoinghe-
modialysis including 535 subjects with
diabetes, however, administration of ro-
suvastatin 10 mg versus placebo did
not reduce nonfatal myocardial infarc-
tion, nonfatal stroke, or cardiovascular
death—a ﬁnding similar to that of an
earlier study with atorvastatin (34)—
suggesting that there may be a point after
which lipid lowering is not beneﬁcial.
Similarly, Go reviewed the Veterans Af-
fairs Diabetes Trial (VADT), concluding
that intensive glycemic treatment does
not appear to be associated with reduc-
tion in adverse outcome, although caus-
ing a fourfold increase in hypoglycemia
(35). Go’s assessment may, however, be
somewhat harsh, as reassessment of the
VADT ﬁndings led to a correction to the
effect that intensive glycemic control was
associated with improvement in all albu-
minuria outcomes (36), and a fascinating
new VADT analysis shows that glucose
lowering reduced cardiovascular events
in those with less coronary artery calciﬁ-
cation (37), suggesting that glycemic
treatment may play an important role
early in the natural history of diabetes.
Combination RAS blockade
Lawrence Krakoff (New York, NY) dis-
cussed the question of combined block-
ade of the RAS at the Mount Sinai
Diabetes conference on 7 January 2010,
asking the question, beneﬁt or harm? He
reviewed the components of the system.
Renin exists in activated and inactivated
forms, but with interesting questions
raised whether the latter actually have bi-
ological activity. Angiotensinogen is syn-
thesized in the liver, inﬂuenced by a
number of factors, with renin leading to
generationofthedecapeptideangiotensin
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involvingtheenzymechymase)leadingto
generation of the octapeptide angiotensin
II (AII), which has multiple roles, includ-
ing proinﬂammatory effects, as do other
components of the system. Aldosterone
secretionisstimulatedbyAIIaswellasby
other factors, in particular elevations in
circulating potassium levels.
The majority of antihypertensive
agents have effects on some of the com-
ponents of the system: -blockers de-
creasing and diuretics and vasodilators
increasing renal renin release, ACEI re-
ducing AII formation, ARB acting (al-
though only partially) at the AII type 1
receptor, and direct renin inhibitors
blocking angiotensin I formation; only
the calcium channel blockers are neutral.
Given the importance of the RAS as an
approach to blood pressure management
and the complexity of the system (38), it
is important to review the limitations of
the existing classes of agents. ACEI will
incompletely decrease AII generation and
have effects on kinin and substance P,
while ARBs are incomplete in their effect
on the AII type 1 receptor and have no
effect on the type 2 receptor. Both ACEI
and ARB lead to feedback increase in ac-
tive renin generation. The direct renin in-
hibitors also are incomplete in their
action, and because of their feedback ef-
fect in increasing inactive renin levels,
Krakoff raised the possibility of adverse
effect if inactive renin has biologic
actions.
The question, then, is whether there
might be value to combining inhibitors of
the RAS acting at multiple levels. A num-
ber of end points could be envisaged, in-
cluding blood pressure and albuminuria
reduction; adverse effects such as hyper-
kalemia, hypotension, and worsening re-
nal function; and outcome beneﬁts
including cardiovascular disease events,
renal disease progression, and, particu-
larly in congestive heart failure (CHF)
studies, prevention of hospitalization.
One potential combination, that of
-blockerswithACEIorARB,showslittle
evidence of additive blood pressure–
lowering effect, although formal studies
are lacking.
The ﬁrst area to be investigated was
the combination of ACEI with ARB treat-
ment; a widely cited positive study (39),
however, was recently retracted after in-
vestigation suggested the possibility of
data fabrication (40). In a study of 405
type 2 diabetic subjects with microalbu-
minuria comparing the ACEI ramipril
alone with the combination of ramipril
plustheARBirbesartan,noadditiveeffect
was observed on either albuminuria or
blood pressure (41), and in a study of
subjects with decreased cardiac function
following myocardial infarction random-
ized to the ARB valsartan, the ACEI cap-
topril, or both, either agent was found to
be effective, but the combination led to a
higher18%rateofadverseeffectsincom-
parisonwiththe12–15%rateswitheither
agent alone (42). Krakoff discussed the
study Go had mentioned of 25,620 high-
risk hypertensive individuals, with either
diabetes or existing vascular disease, ran-
domizedtotheARBtelmisartan,ramipril,
or both, and noted the remarkable
achievement of 99.8% follow-up over a
median of 56 months. There was, he
pointed out, somewhat greater blood
pressure lowering with the combination
but a greater likelihood of hypotension
and of renal dysfunction and no differ-
ence in CV mortality, myocardial infarc-
tion, stroke, or hospitalization for CHF
(29).Onlyinastudyof5,010participants
with CHF randomized to usual care (typ-
ically including an ACEI) alone or with
addition of valsartan was there a 24% re-
duction in hospitalization (43), and a re-
cent subset analysis showed that the
beneﬁt extended to subjects with renal
insufﬁciency, although the ARB did in-
crease the likelihood of hyperkalemia in
thesepatientsfrom4.5to8.5%(44).Kra-
koff concluded that there is little beneﬁt
of combined ACEI/ARB in blood pressure
andlittledifferenceincardiovascularout-
come, with a suggestion that outcome is
worse with the combination in subjects
studied after myocardial infarction.
The topic of combination treatment
addressing RAS components has received
new impetus with the direct renin in-
hibitor aliskiren. A study of 2,000
hypertensive patients showed somewhat
greater blood pressure lowering with
aliskiren in combination with valsartan
than with either agent alone, although
with a greater likelihood of hyperkalemia
(45); Krakoff reviewed another study Go
had described of type 2 diabetic subjects
with hypertension and nephropathy re-
ceiving aliskiren plus losartan or losartan
alone and noted that blood pressure dif-
ferencesmayhavebeenlessenedbyuseof
other agents, although pointing out that
there was again a trend to more frequent
hyperkalemia (28). Similar ﬁndings were
reported in a crossover trial of 26 type 2
diabetic subjects with albuminuria, sub-
jects receiving aliskiren or irbesartan
alone or the combination, the latter lead-
ing to signiﬁcantly greater reduction in
urinary albumin excretion. In the study,
both agents individually reduced GFR
and there was greater such effect after
combined treatment (46). In a study of
patients with CHF receiving either an
ACEI or an ARB, aliskiren reduced basic
natriuretic peptide and urine aldosterone
with some evidence of improvement in
left ventricular function (47); as yet there
is no evidence of improvement in clinical
outcome in such patients. The combina-
tionofdirectrenininhibitionwithARBor
ACEImay,then,offerbeneﬁt,butKrakoff
termed the evidence for this as not being
strong and pointed out that from a ﬁnan-
cial perspective the 30-fold greater cost
of such agents than ACEI makes it some-
what difﬁcult to strongly recommend
their use.
Additional studies
A number of studies presented at the
American Diabetes Association Scientiﬁc
Sessions shed further light on these top-
ics. Ou et al. (abstract 175) found mean
serum 25(OH)D levels of 26 vs. 23 ng/ml
in 168 diabetic vs. 85 control subjects.
Amongdiabeticpatients,25(OH)Dcorre-
lated with weight, blood pressure, fasting
glucose, and A1C and negatively with age
and HDL cholesterol, suggesting poten-
tialbeneﬁtofsupplementation.Naiketal.
(abstract 92) studied 375 subjects and
found that vitamin D deﬁciency was asso-
ciated with an increased likelihood of de-
velopmentofcoronaryarterycalciﬁcation
over 3-year follow-up. Philippe et al. (ab-
stract 667) reported decreased fecal elas-
tase and/or chymotrypsin in 92 of 458
diabetic patients; those with deﬁciency of
both enzymes had lower vitamins E, D,
and A levels and a greater likelihood of
insulin deﬁciency, suggesting that pan-
creatic exocrine as well as endocrine deﬁ-
ciency states may not be uncommon in
diabetes and giving a potential mecha-
nism for the association of diabetes with
vitamin D deﬁciency.
Konoshita et al. (abstract 31) screened
polymorphisms in the RAS and found
that the response to the ARB valsartan
was greater in subjects with higher blood
pressure and in those with diabetes, but
alsowasgreaterinCChomozygotesofthe
reninC-5312Tgene.Chatterjeeetal.(ab-
stract 282) followed 13,398 participants
in the Atherosclerosis Risk in Communi-
ties (ARIC) Study for 9 years, with 1,484
subjects developing diabetes. Serum po-
tassium was inversely associated with se-
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whohadpotassium5mEq/l,thosewith
levels 4.5–4.99 had 1.4-fold and those
with levels 4.5 had 1.7-fold increase in
risk of diabetes, respectively, controlling
for use of ACEIs, -blockers, and diuret-
ics. Perhaps related to this association of
higher potassium with less diabetes, Mu-
hlestein et al. (abstract 99) found that
among 357 diabetic subjects with angio-
graphically diagnosed CHD plasma renin
activity 0.6 ng   ml
1   h
1 was associ-
ated with more than a twofold reduction
in mortality.
Bountouvis et al. (abstract 796)
treated20type2diabeticindividualswith
mean GFR 51 ml/min per 1.73 m
2 with
spironolactone (25 mg daily) and found
at 3 months an 8-mmHg reduction in
24-h ambulatory diastolic blood pressure
but a 0.5 mmol   l
1   l
1 increase in po-
tassium,withoutchangeinbrachialartery
ﬂow–mediated dilation, A1C, or GFR. At
12 months, however, there was a trend to
worsening GFR and loss of the effect on
blood pressure, suggesting that beneﬁts
from aldosterone blockade might be out-
weighed by risks.
Other studies reported interesting as-
sociations of diabetes with albuminuria.
De Cosmo et al. (abstract 826) reported
proline-12-alanine polymorphism geno-
type ﬁndings among 1,119 hypertensive,
initially normoalbuminuric type 2 dia-
betic subjects and showed that those with
the alanine genotype, which is associated
with lower weight, were 45% as likely to
develop microalbuminuria as those ho-
mozygous for the proline polymorphism,
but, interestingly, that those in the latter
group receiving ACEI treatment were less
likelytodevelopalbuminuria.Voulgariet
al. (abstract 819) enrolled 193 newly di-
agnosed type 2 diabetic cigarette smokers
with microalbuminuria in a smoking ces-
sation lifestyle program. Among the 95
whoquit,albuminuriaat1yeardecreased
by 38%, whereas those continuing to
smoke had a 16% reduction during this
period. Brix et al. (abstract 28) reported
that YKL-40, a marker of plaque rupture,
was increased by 22 and 78% in subjects
with micro-and macroalbuminuria over
levels in normoalbuminuric type 2 dia-
betic subjects, as well as being associated
with serum creatinine and age. Moham-
medi et al. (abstract 30) studied poly-
morphisms in the enzyme superoxide
dismutase 1 in 1,278 type 1 diabetic
patients from three cohorts, ﬁnding as-
sociations of speciﬁc alleles with mi-
croalbuminuria and hypertension.
Kim et al. (abstract 790) found urate
levels of 4.5, 5.0, and 5.6 mg/dl among
320, 94, and 41 type 2 diabetic subjects
withnormo-,micro-,andmacroalbumin-
uria, respectively, independent of age,
sex, creatinine clearance, A1C, lipids, di-
abetesduration,bloodpressure,plasmin-
ogen, ﬁbrinogen, or C-reactive protein
levels. In multivariate regression analysis,
other signiﬁcant determinants of albu-
minuria were ﬁbrinogen, total choles-
terol, and systolic blood pressure. Uric
acid levels are associated with reduction
in insulin sensitivity, perhaps because of
change in tubular urate handling, and a
number of studies also suggested associa-
tion with the development of diabetes.
Kodamaetal.(abstract1002)foundthata
1 mg/dl increase in uric acid was associ-
ated with an 8% increase in diabetes risk
in a meta-analysis of 11 studies adjusting
for BMI and blood pressure. Kramer et al.
(abstracts 660 and 1044) reported that
2,342 subjects undergoing glucose toler-
ance testing and followed for a mean of
13.2 years showed, for every 2 mg/dl in-
crease in serum uric acid, 25, 20, and
20% increases in all-cause mortality ad-
justed for age, smoking, BMI, alcohol, ex-
ercise, diuretic use, and estimated GFR
among subjects with normal and im-
paired glucose tolerance and with diabe-
tes, respectively, suggesting that the
associationofuratewithmortalitymaybe
independentofitsassociationwithabnor-
mal glucose metabolism. Of 566 subjects
having follow-up glucose tolerance test-
ing, 55 developed type 2 diabetes; for
each 1 mg/dl increase in urate, the risk
increased 50%, adjusting for age, sex,
BMI,diureticuse,andGFR,withriskonly
signiﬁcant among those with impaired
fasting glucose at baseline. Shankar et al.
(abstract 1048) conﬁrmed an association
of uric acid with diabetes risk in 2,868
subjects followed over 15 years, indepen-
dent of age, sex, education, cigarette and
alcohol use, blood pressure, lipids, and
A1C, with the likelihood of diabetes 1.2-,
1.7-, and 1.9-fold increased in the 2nd,
3rd, and 4th tertiles of serum uric acid
level, respectively.
Otheraspectsofhypertensionandre-
nal disease in diabetes were addressed as
well. Schwartz et al. (abstract 112) stud-
ied 57 type 2 diabetic subjects with
chronic kidney disease, ﬁnding that cre-
atinine levels decreased 8, 21, and 19%
and estimated glomerular ﬁltration rate
increased 9, 29, and 27%, respectively, at
25, 75, and 150 mg daily doses of the
antioxidant inﬂammation modulator Bar-
doxolone methyl. Watanabe et al. (ab-
stract 809) reported that levels of insulin-
likegrowthfactorbindingprotein-related
protein 1, a member of the IGFBP family
with low afﬁnity for IGF but a high and
speciﬁc afﬁnity for insulin, are increased
in human renal proximal epithelial cells
incubated with transforming growth fac-
tor-1, with levels of the protein in-
creased in urine of persons with diabetes,
suggesting it to be a marker of tubular
injury. Ghanim et al. (abstract 807) re-
portedthata4-hinsulininfusionreduced
transforming growth factor , plasmino-
gen activator inhibitor-1 and intercellular
adhesion molecule-1 in ten type 2 dia-
betic patients, suggesting potential bene-
ﬁt. Khalil et al. (abstract 26) found
signiﬁcantly greater amino acid infusion-
induced increase in glomerular ﬁltration
rate and renal plasma ﬂow, and decrease
in renal vascular resistance, in children of
type 1 diabetic mothers than of type 1
diabetic fathers, suggesting that in utero
exposure to the diabetic environment
may lead to reduced renal reserve.
Leichter et al. (abstract 26-LB) found
that among 284 persons undergoing eye
screeningthepresenceofarcusseniliswas
associated with fasting glucose and blood
pressure as well as with age; there was no
association with lipids or body weight.
Waki and Terasaki (abstract 395) re-
ported the outcome of simultaneous pan-
creas kidney transplants during the
period from 1987–2007, ﬁnding that
graft survival has been stable since 1995.
Rayhill and Roberts (abstract 396) re-
ported that both greater donor age and
donor BMI 30 were associated with
lower graft survival. Kazempour-Ardebili
et al. (abstract 401) performed 48-h con-
tinuous glucose monitoring on 17 dia-
betic persons with end-stage renal
insufﬁciency, ﬁnding 24-h mean glucose
of227versus176mg/dlondialysisversus
nondialysis days, with nadir glucose oc-
curring in 14 of the patients within 24 h
after dialysis.
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